VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its ...

Review the side-effects of Rotigotine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- The ...

This open-label study was the first study of rotigotine transdermal system used as an adjunct to treatment with an oral DA. The majority of patients in this study were Hoehn and Yahr stage II-III, and ...

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product ...

VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to report an update on its commercialization plan for its ...

January 10, 2007 — Transdermal rotigotine, a dopamine agonist, is effective in controlling symptoms of early-stage Parkinson's disease (PD), a new study suggests. The multicenter, randomized, ...

Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...

A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...

BioNxt Solutions (OTCQB:BNXTF) has executed an agreement to carry out comparative drug absorption study for its transdermal (TDS) Rotigotine patch for the treatment of Parkinson's disease. The company ...